Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2015 1
2017 1
2018 1
2019 4
2020 8
2021 8
2022 14
2023 11
2024 7
2025 9
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators. Kastritis E, et al. Among authors: bumma n. N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631. N Engl J Med. 2021. PMID: 34192431 Clinical Trial.
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
Bumma N, Richter J, Jagannath S, Lee HC, Hoffman JE, Suvannasankha A, Zonder JA, Shah MR, Lentzsch S, Baz R, Maly JJ, Namburi S, Pianko MJ, Ye JC, Wu KL, Silbermann R, Min CK, Vekemans MC, Munder M, Byun JM, Martínez-Lopez J, Cassady K, DeVeaux M, Chokshi D, Boyapati A, Hazra A, Yancopoulos GD, Sirulnik LA, Rodriguez Lorenc K, Kroog GS, Houvras Y, Dhodapkar MV. Bumma N, et al. J Clin Oncol. 2024 Aug 1;42(22):2702-2712. doi: 10.1200/JCO.24.01008. Epub 2024 Jun 16. J Clin Oncol. 2024. PMID: 38879802 Free PMC article. Clinical Trial.
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Bumma N, Kaufman JL, Medvedova E, Kovacsovics T, Rosenzweig M, Sanchorawala V, Qin X, Vasey SY, Weiss BM, Vermeulen J, Merlini G, Comenzo RL. Palladini G, et al. Among authors: bumma n. Blood. 2020 Jul 2;136(1):71-80. doi: 10.1182/blood.2019004460. Blood. 2020. PMID: 32244252 Free PMC article. Clinical Trial.
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG. Voorhees PM, et al. Among authors: bumma n. Lancet Haematol. 2023 Oct;10(10):e825-e837. doi: 10.1016/S2352-3026(23)00217-X. Epub 2023 Sep 11. Lancet Haematol. 2023. PMID: 37708911 Clinical Trial.
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
Callander NS, Silbermann R, Kaufman JL, Godby KN, Laubach J, Schmidt TM, Sborov DW, Medvedova E, Reeves B, Dhakal B, Rodriguez C, Chhabra S, Chari A, Bal S, Anderson LD Jr, Dholaria BR, Nathwani N, Hari P, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Giri S, Costa LJ, Usmani SZ, Richardson PG, Voorhees PM. Callander NS, et al. Among authors: bumma n. Blood Cancer J. 2024 Apr 22;14(1):69. doi: 10.1038/s41408-024-01030-w. Blood Cancer J. 2024. PMID: 38649340 Free PMC article. Clinical Trial.
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies.
Umyarova E, Pei C, Pellegrino W, Zhao Q, Sharma N, Benson D, Cottini F, Bezerra E, Brammer J, Bumma N, Choe H, Denlinger N, Devarakonda S, Khan A, Penza S, Rosko A, Vasu S, Wall S, Alinari L, Baiocchi R, Bond DA, Christian B, Hanel W, Maddocks K, Reneau J, Sawalha Y, Habib A, Sigmund A, Voorhees TJ, de Lima M, Epperla N. Umyarova E, et al. Among authors: bumma n. J Hematol Oncol. 2025 Mar 18;18(1):30. doi: 10.1186/s13045-025-01676-4. J Hematol Oncol. 2025. PMID: 40098061 Free PMC article.
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.
Chari A, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Voorhees PM, Usmani SZ, Richardson PG. Chari A, et al. Among authors: bumma n. Blood Cancer J. 2024 Jul 8;14(1):107. doi: 10.1038/s41408-024-01088-6. Blood Cancer J. 2024. PMID: 38977707 Free PMC article. Clinical Trial.
Hereditary Transthyretin Amyloidosis in Patients Referred to a Genetic Testing Program.
Bhatt K, Delgado DH, Khella S, Bumma N, Karam C, Keller A, Rosen AM, Bozas A, Shea A, Towne MC, Polfus LM, Kaeser GE, Sanjurjo V, Shah KB. Bhatt K, et al. Among authors: bumma n. J Am Heart Assoc. 2024 Dec 3;13(23):e033770. doi: 10.1161/JAHA.123.033770. Epub 2024 Nov 22. J Am Heart Assoc. 2024. PMID: 39575713 Free PMC article.
Management recommendations for kidney transplantation in patients with plasma cell dyscrasia.
Murakami N, Blosser CD, Webber AB, Gupta G, Singh N, Boppana S, Master S, Parasuraman R, Campagnaro EL, Java A, Sprangers B, Bhasin-Chhabra B, Lum E, Khirfan D, Alexander MP, Molnar MZ, Benes B, Thakur AK, Bumma N, Karam S, Hultcrantz M, Bridoux F, Sanchorawala V, Leung N, Landau H. Murakami N, et al. Among authors: bumma n. Kidney Int. 2025 Nov;108(5):780-790. doi: 10.1016/j.kint.2025.07.011. Epub 2025 Jul 28. Kidney Int. 2025. PMID: 40738478 Review.
Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
Lee HC, Bumma N, Richter J, Zonder JA, Hoffman JE, Zhou ZY, García-Horton V, Fillbrunn M, Wang H, Mattera M, Ma W, Inocencio TJ, Xu Y, Bergrath E, Harnett J, Roccia T, Knorr K, Kroog GS, Lorenc KR, Ma Q, Jagannath S. Lee HC, et al. Among authors: bumma n. Clin Lymphoma Myeloma Leuk. 2025 Dec;25(12):897-909.e8. doi: 10.1016/j.clml.2025.06.014. Epub 2025 Jun 22. Clin Lymphoma Myeloma Leuk. 2025. PMID: 40750499 Free article.
54 results